Summary We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, , could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). and NSE were measured retrospectively in 101 newly diagnosed untreated patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area under curve (AUC) of 'receiver operator characteristics' of ProGRP(31 -98) with that of NSE, ProGRP(31-98) was the more powerful marker in the diagnosis of SCLC (P=0.0001). Serum levels of were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P=0.0082). ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed small-cell/large-cell carcinoma (P=0.02). In serial measurement in 16 patients responding to treatment, a high degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response during the second week after treatment (P=0.0045). These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.
A number of serum components have been Proposed as markers of the extent of disease and of the clinical response to cytotoxic therapy in patients with small-cell lung cancer (SCLC) (Bates and Longo, 1987) . Among these, neuronspecific enolase (NSE) has been Proved sufficiently sensitive and specific for general use in the diagnosis and management of these patients (Akoun et al., 1985; Ariyoshi et al., 1983; Carney et al., 1982; Cooper et al., 1985; Esscher et al., 1985; Nou et al., 1990) . However, studies on NSE have shown a number of weaknesses with respect to its specificity for SCLC; these include a relatively high false-positive rate in patients with non-malignant lung diseases (Esscher et al., 1985) and non-small-cell lung cancer (NSCLC) (Ariyoshi et al., 1983; Cooper et al., 1985; Esscher et al., 1985; Notomi et al., 1985) and an increase in levels by haemolysis (Esscher et al., 1985; Notomi et al., 1985) . Accordingly, a more specific tumour marker that can reliably and rapidly reflect the diagnosis and efficacy of treatment for patients with SCLC has been sought.
McDonald et al. (1978) isolated a 27 amino acid peptide homologous to the carboxy-terminal of bombesin from porcine stomach and named this compound gastrin-releasing peptide (GRP). Spindel et al. (1984) prepared and cloned cDNAs derived from mRNA from a human pulmonary carcinoid tumour that had strong immunoreactivity to GRP. A number of investigators have reported that immunoreactive GRP is present in the fetal and neonatal lung (Wharton' et al., 1978; Yamaguchi et al., 1983) and in primary lung cancer, especially in SCLC (Erisman et al., 1982; Moody et al., 1981; Wharton et al., 1978) . Additionally, immunohistochemical analysis (Cuttitta et al., 1988) of ProGRP fragments (GGAPs) was also reported to immunostain both GRP and GGAP in SCLC cell lines and human SCLC tumours. This finding suggested the possibility that the plasma GRP level could serve as a marker of SCLC. ProGRP(31-98), a region common to the three types of previously cloned human ProGRP molecules, has recently been synthesised (Aoyagi et al., 1995; Miyake et al., 1994) . Aoyagi et al. (1995) have now developed a highly sensitive ELISA system which detects serum immunoreactive ProGRP(31-98).
The present study was undertaken to identify the relationship between this marker and other clinical factors in SCLC. In addition, we compared its discriminatory power with that of NSE, the marker presently used for SCLC.
Materials and methods Patients A total of 212 consecutive samples (Table I) well of human sera or standard ProGRP(3 1-98). The reaction mixture was incubated for 1 h at 37°C. The plates were washed and horseradish peroxidase-conjugated rabbit polyclonal antibody was added to each well and further incubated for 30 min at room temperature. After the plates were washed again, the colour of the enzyme reaction was developed by the addition of substrate solution containing o-phenylenediamine plus hydrogen peroxide, and stopped by adding 4 M sulphuric acid. The absorbance of each well at 492 nm was measured by a Corona MTP-32 microplate reader (Conona Electric, Ibaraki, Japan). The variability and accuracy of this assay will be described by Aoyagi et al. (1995) . Briefly, this ELISA for ProGRP(31-98) can easily be measured within about 2 h in clinical use. The coefficients of variation for intra-assay precision and interday reProducibility in a panel of sera both ranged from 1.7% to 6.8% respectively. No interference was seen from blood elements in serum or anticoagulants, nor was any cross-reactivity with GRP, bombesin, neurokinin A, galanin, calcitonin generelated peptide, adrenocorticotropic hormone or NSE seen at a concentration of 1 ,ug ml-1 for each. NSE levels were determined by a sandwich enzyme immunoassay as described by Ishiguro et al. (1982) . All serum samples were assayed blind of clinical information.
Histological diagnosis
The primary diagnosis of SCLC was made on materials obtained by bronchoscopy, mediastinoscopy and/or scalene node biopsy. All diagnostic materials were reviewed by one of the authors. Diagnostic criteria for SCLC were those of the current IASCL classification (Hirsch et al., 1988) . The diagnosis of SCLC was made on cytological materials as well as histological materials, but morphological suibclassification was made only on the histological materials. All slides from patients with mixed small-cell/large-cell carcinoma for this analysis were reviewed independently by two pathologists, who agreed on the diagnosis for each patient.
Statistical analysis Data were represented as median and the 90th and 75th percentiles of variability. All data other than those of the receiver operator characteristics (ROC) curves were analysed by non-parametric methods. The Mann-Whitney U-test was used for the comparison of two groups of random samples. Multiple comparisons were performed with the KruskalWallis one-way analysis. To evaluate the accuracy of the two different markers, the areas under the two ROC curves were statistically compared using a univariate z-score test by the CLABROC Program (Metz, 1991) . To compare the levels of markers before and after treatment, the Wilcoxon single-rank test was used. Percentages in different groups were compared using the chi-square test.
ROC curves, which correlate with the true-and falsepositive rate (sensitivity and 1 minus specificity respectively), were constructed using the CLABROC Program (Metz, 1991) in an attempt to compare the accuracy of ProGRP(31-98) and NSE. In addition, the areas under the curves of the two markers were calculated and analysed using the same Program. This Program calculates maximum likelihood estimates of the parameters of a 'bivariate binormal' model for continuously distributed data from two potentially correlated diagnostic tests. It thus estimates the binormal ROC curves implied by those data and their correlation, and also calculates the statistical significance between the two ROC curves estimated using a univariate z-score test of the difference between the area under the two ROC curves. The CLABROC algorithm, developed by Professor CE Metz at the University of Chicago, is a version of the CORROC algorithm (Metz et al., 1984) that has been modified to analyse continuously distributed data (Metz et al., 1990) .
Results

Cut-off value calculation
In order to compare our results for the different tumour markers under the same conditions we followed the recommendations of the 'Hamburg Group for the Standardisation of Tumour Markers' (Klapdor, 1992) . Cut-off values for each reference group were fixed at a specificity of 95%. Thus, in 95% of the non-malignant lung diseases, ProGRP(31 -98) values were below 33.8 pg ml-and NSE values were below 10.6 ng ml-.
Tumour marker distribution and diagnostic sensitivity The distribution of ProGRP(31-98) and NSE concentrations in regard to the histological types of lung cancer and nonmalignant lung diseases is illustrated in Figure 1 SCLC, NSCLC and non-malignant lung diseases were 234.4 (31.7-894.8), 22.6 (17.7-30 .2) and 12.4 (9.5-18.6) pg ml-' respectively. This ProGRP(3 1-98) level in SCLC was significantly different (P=0.0001) from that in NSCLC and benign lung diseases. Serum ProGRP(3 1-98) levels were significantly higher in SCLC than in NSCLC (P=0.0001). Based on a specificity of 95% vs non-malignant lung diseases, ProGRP(31-98) showed a true-positive test result in 72.3% of SCLC and 14.4% of NSCLC cases. In contrast, NSE showed a true-positive result in 62.4% of SCLC and 33.3% of NSCLC cases.
Area under ROC curves for the tumour markers To confirm the correlations of true-and false-positive rates (sensitivity and 1 minus specificity, respectively) for a series of cut-off points for any test, ROC curves for ProGRP(31-98) and NSE in SCLC were prepared (Figure 2 ). Calculation of areas under the ROC curves using the CLABROC Program showed a significant difference between the two markers (P = 0.0001). Table II . Significantly higher ProGRP(31-98) levels were observed in patients with extensive SCLC than in those with limited disease (P = 0.0082). NSE levels were also significantly higher in patients with extensive SCLC than in those with limited SCLC (P=0.0045). Positive rates of ProGRP(31-98) were 67.2% in 61 limited and 80% in 40 extensive cases (P= 0.24). In contrast, positive rates of NSE were 50.8% and 80% respectively (P = 0.006). ProGRP and NSE levels according to metastases The relationship of serum ProGRP(31-98) levels to the site of metastasis and to the number of metastasised organs was analysed (Table II) . Although ProGRP(31-98) levels in the 40 patients with extensive SCLC were higher in the 11 patients who had two or more metastatic sites than in the 29 who had only one site, there was no significant difference between the groups (P = 0.22). The same trend was seen for NSE (P=0.40).
In addition, the relationship between raised tumour marker levels and the site of metastasis was analysed for 40 patients in whom a dominant site could be clearly established, namely in the liver, bone marrow, brain and bone in 10 (25%), 10 (25%), 7 (17.5%) and 7 (17.5%) patients respectively (Table II) Figure 3 . ProGRP(31 -98) levels were significantly higher in pure small-cell carcinoma (median, 290.2; interquartile range, 36.6-888.2 pg ml-') than in small-cell/largecell carcinoma (median, 21.9; interquartile range, 18.8-47.2 pg ml-'; P = 0.02). In contrast, there was no significant difference (P = 0.06) in NSE levels between the pure small-cell carcinoma and the mixed small-cell/large-cell form.
Correlation between serial plasma ProGRP(31-98) levels and response to therapy Serial ProGRP(3 1-98) and NSE levels obtained during induction therapy were evaluated in 16 patients (Figure 4) . All patients responded to treatment, two achieving a complete response and 14 a partial response. Ten of these patients had initial ProGRP(3 1-98) levels greater than 33.8 pg ml-'. These patients all showed a marked decrease in ProGRP(31-98) level after treatment, with values on day 14 significantly decreased compared with pretreatment levels (Wilcoxon; P=0.0045). On a semilog plot, these decreases were almost linear within 2 weeks after treatment. However, there was no clear correlation between serial serum NSE level and response to treatment.
In three patients with positive pretreatment ProGRP(31-98) and NSE levels, these levels at the time of clinical relapse were determined. In one patient (Figure 4 , patient A), only ProGRP was rising before clinical detection of Progression.
Discussion
In our series, raised ProGRP(31-98) levels were found at diagnosis in 72.3% of SCLC patients and 14.4% of NSCLC patients. In contrast, NSE showed a true-positive result in 62.4% of SCLC patients and 33.3% of NSCLC patients. (Table II) . This finding may indicate the existence of a correlation between tumour burden and serum ProGRP(3 1-98) level.
Carney and colleagues (1985) identified several biomarkers in cell lines of SCLC including L-dopa decarboxylase (DDC), NSE, GRP and BB isozyme of creatine kinase (CK-BB). In further analysis, classic SCLC lines of histologically pure small-cell carcinoma expressed elevated levels of all four biomarkers. In contrast, variant SCLC lines of histologically mixed small-cell/large-cell carcinoma had undetectable levels of DDC and GRP, but continued to express NSE and CK-BB. Our results seem to correlate well with these results in SCLC cell lines, namely that ProGRP(31-98) levels are low and NSE levels relatively high in patients with mixed smallcell/large-cell carcinoma (Figure 3 ). Another interesting finding in our study was the detection of a minor elevation in ProGRP(31-98) level in some patients with mixed smallcell/large-cell carcinoma. As suggested by Holst et al. (1989) , the reason for this may be that tumour-derived GRP is metabolised so quickly that it escapes detection (Knigge et al., 1984) whereas ProGRP(31-98) might survive longer in the circulation.
Although we did not analyse serum ProGRP(3 1-98) levels in patients with neuroendocrine lung tumours except SCLC, Yamaguchi et al. (1983) reported that immunoreactive GRP was found in five of the 12 bronchial carcinoid tumours (42%). Therefore, we speculate that the elevation of serum ProGRP(31-98) levels in bronchial carcinoid tumours would be also indicated at the rate like GRP in terms of concordant expression of GRP and ProGRP(31-98).
In serial determinations of serum ProGRP(31-98) level, a significant decrease in ProGRP(3 1 -98) occurred within 2 weeks after treatment even when a major response was not observed (Figure 4) . Furthermore, these decreases in ProGRP(3 1 -98) levels were linear on the semilog plot within 2 weeks after treatment (Figure 4) . Miyake et al. (1994) also demonstrated an excellent correlation between ProGRP(3 1-98) level and therapeutic response. Although they measured levels only twice, before and at 1 month after therapy, levels had decreased by the second measurement to an undetectable range in all cases showing a complete response and in one-third of cases showing a partial response. These findings indicate that the monitoring of ProGRP(31-98) level during induction treatment will allow both the prediction and confirmation of tumour response. Furthermore, if ProGRP(3 1 -98) levels reflect the actual tumour burden, the decreasing pattern illustrated in Figure 4 may show a log reduction in the number of tumour cells by cytotoxic treatment. However, the number of our follow-up cases was too small to lead to a conclusion for monitoring, therefore we recently conducted a Prospective trial to monitor this marker.
The usefulness of ProGRP(3 1-98) as the indicator of early relapse was not shown in our small number of patients with the long-term follow-up for this marker. However, the early detection of relapsing SCLC would not offer advantages to the patient, because the therapeutic measures in case of relapse are still rather limited.
The practical value of a tumour marker is determined by three factors: the frequency with which the marker is detected in the tumour population; the correlation between the blood level of the marker and the tumour burden; and the availability of effective treatment for the tumour (McKenzie et al., 1977) . Data from our study suggest that ProGRP(31 -98) apProaches these criteria as a tumour marker of value in the diagnosis and treatment planning of SCLC.
